Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders

Journal of Clinical Medicine

Volumn 6, Issue 7, 2017, Pages

  Stepien, Karolina M ^a   Heaton, Robert ^b   Rankin, Scott ^b   Murphy, Alex ^b   Bentley, James ^b   Sexton, Darren ^b   Hargreaves, Iain P ^b  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Catalase; Coenzyme Q10; Electron transport chain; Glutathione; Methylmalonic acid; Methylmalonic acidemia; Mitochondria; Nitric oxide synthase; Nitrosative stress; Oxidative stress; Peroxisome; Phenylketonuria; Reactive nitrogen species; Reactive oxygen species; Sepsis; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; CHEMOKINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTIC ACID; NITRIC OXIDE; PHENYLALANINE 4 MONOOXYGENASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UBIDECARENONE; VERY LONG CHAIN FATTY ACID;

ADRENOLEUKODYSTROPHY; AMINO ACID METABOLISM; BIOGENESIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISORDERS OF PEROXISOMAL FUNCTIONS; FATTY ACID OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERPHENYLALANINEMIA; INFANTILE REFSUM DISEASE; LACTIC ACIDOSIS; METABOLIC DISORDER; METHYLMALONIC ACIDEMIA; OXIDATIVE STRESS; PEROXISOME; PHENYLKETONURIA; RESPIRATORY CHAIN; REVIEW; SEPSIS; XERODERMA PIGMENTOSUM; ZELLWEGER SYNDROME;

EID: 85030683478     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6070071     Document Type: Review

References (190)

1. Sosa, V.; Moline, T.; Somoza, R.; Paciucci, R.; Kondoh, H.; Leonard, L. Oxidative stress and cancer: An overview. Aging Res. Rev. 2013, 12, 376-390.
2. Brealey, D.; Brand, M.; Hargreaves, I.; Heales, S.; Land, J.; Smolenski, R.; Davis, N.A.; Cooper, C.E.; Singer, M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360, 219-223.
3. Heales, S.J.; Bolanos, J.P.; Brand, M.P.; Clark, J.B.; Land, J.M. Mitochondrial damage: An important feature in a number of inborn errors of metabolism? J. Inherit. Metab. Dis. 1996, 19, 140-142.
4. Moyano, D.; Vilaseca, M.A.; Pineda, M.; Campistol, J.; Vernet, A.; Poo, P.; Artuch, R.; Sierra, C. Tocopherol in inborn errors of intermediary metabolism. Clin. Chim. Acta 1997, 263, 147-155.
5. Sierra, C.; Vilaseca, M.A.; Moyano, D.; Brandi, N.; Campistol, J.; Lambruschini, N.; Cambra, F.J.; Deulofeu, R.; Mira, A. Antioxidant status in hyperphenylalaninemia. Clin. Chim. Acta 1998, 276, 1-9.
6. Artuch, R.; Vilaseca, M.A.; Moreno, J.; Lambruschini, N.; Cambra, F.J.; Campistol, J. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am. J. Clin. Nutr. 1999, 70, 892-895.
7. Fisberg, R.M.; Silva-Femandes, M.E.; Fisberg, M.; Schmidt, B.J. Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria. Nutrition 1999, 15, 449-452.
8. Van Bakel, M.M.E.; Printzen, G.; Wermuth, B.; Wiesmann, U.N. Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am. J. Clin. Nutr. 2000, 72, 976-981.
9. Rani, V.; Deep, G.; Singh, R.K. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016, 148, 183-193.
10. Kolker, S.; Schwab, M.; Horster, F.; Sauer, S.; Hinz, A.; Wolf, N.I.; Mayatepek, E.; Hoffmann, G.F.; Smeitink, J.A.M.; Okun, J.G. Methylmalonic acid, a biochemical hallmark of methylmalonic acidurias but no inhibitor of mitochondrial respiratory chain. J. Biol. Chem. 2003, 278, 47388-47393.
11. Schonfeld, P.; Reiser, G. Rotenone-like action of the branch chain phytanic acid induces oxidative stress in mitochondria. J. Biol. Chem. 2006, 281, 7136-7142.
12. Zapelini, P.H.; Retin, G.T.; Cardoso, M.R.; Ritter, C.; Ritter, C.; Klamt, F.; Moreira, J.C.; Streck, E.L.; Dal-Pizzol, F. Antioxidant treatment reverses mitochondrial dysfunction in a sepsis animal model. Mitochondrion 2008, 8, 211-218.
13. Paradies, G.; Ruggiero, F.M.; Petrosillo, G.; Quagliariello, E. Peroxidative damage to cardiac mitochondria: Cytochrome c oxidase and cardiolipin alterations. FEBS Lett. 1998, 424, 155-158.
14. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1-13.
15. Rocha, C.R.; Martins, M.J. Oxidative stress in phenylketonuria: Future directions. J. Inherit. Metab. Dis. 2012, 35, 381-398.
16. Prauchner, C.A. Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy. Burns 2016, 43, 471-485.
17. Scriver, C.R.; Kaufman, S.; Eisensmith, R.C.; Woo, S.L.C. The phenylalaninemias. In The Metabolic and Molecular Bases of Inherited Disease, 7th ed.; Scriver, C.R., Beaudet, A.L., Valle, D., Sly, W.S., Eds.; McGraw-Hill: New York, NY, USA, 1995; pp. 1015-1075.
18. Williams, R.A.; Mamotte, C.D.; Burnett, J.R. Phenylketonuria: An inborn error of phenylalanine metabolism. Clin. Biochem. Rev. 2008, 29, 31-41.
19. Velema, M.; Boot, E.; Engelen, M.; Hollak, C. Parkinsonism in phenylketonuria: A consequence of dopamine depletion? JIMD Rep. 2015, 20, 35-38.
20. Krause, W.; Halminski, M.; McDonald, L.; Demure, P.; Salvo, R.; Friedes, S.R.; Elsas, L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. J. Clin. Investig. 1985, 75, 40-48.
21. Ushakova, G.A.; Gubkina, H.A.; Kachur, V.A.; Lepekhin, E.A. Effect of experimental hyperphenylalaninemia on the postnatal rat brain. Int. J. Dev. Neurosci. 1997, 15, 29-36.
22. Ercal, N.; Aykin-Burns, N.; Gurer-Orhan, H.; McDonald, J.D. Oxidative stress in a phenylketonuria animal model. Free Radic. Biol. Med. 2002, 32, 906-911.
23. Pietz, J. Neurological aspects of adult phenylketonuria. Curr. Opin. Neurol. 1998, 11, 679-688.
24. Smith, I.; Knowles, J. Behaviour in early treated phenylketonuria: A systematic review. Eur. J. Pediatr. 2000, 159, S89-S93.
25. Berry, S.A.; Brown, C.; Grant, M.; Greene, C.L.; Jurecki, E.; Koch, J.; Moseley, K.; Suter, R.; van Calcar, S.C.; Wiles, J. et al. Newborn screening 50 years later: Access issues faced by adults with PKU. Genet. Med. 2013, 15, 591-599.
26. Weglage, J.; Pietsch, M.; Funders, B.; Koch, H.G.; Ullrich, K. Neurological findings in early treated phenylketonuria. Acta Paediatr. 1995, 84, 411-415.
27. Dyer, C.A. Comments on the neuropathology of phenylketonuria. Eur. J. Pediatr. 2000, 159, S107-S108.
28. Huttenlocher, P.R. The neuropathology of phenylketonuria: Human and animal studies. Eur. J. Pediatr. 2000, 159, S102-S106.
29. Rocha, J.C.; Martel, F. Large neutral amino acids supplementation in phenylketonuric patients. J. Inherit. Metab. Dis. 2009, 32, 472-480.
30. Duarte, J.M.; Schuck, P.F.; Wenk, G.L.; Ferreira, G.C. Metabolic disturbances in diseases with neurological involvement. Aging Dis. 2013, 5, 238-255.
31. Sirtori, L.R.; Dutra-Filho, C.S.; Fitarelli, D.; Sitta, A.; Haeser, A.; Barschak, A.G.; Wajner, M.; Coelho, D.M.; Llesuy, S.; Bello-Klein, A. et al. Oxidative stressvin patients with phenylketonuria. Biochim. Biophys. 2005, 1740, 68-73.
32. Sitta, A.; Barschak, A.G.; Deon, M.; Barden, A.T.; Biancini, G.B.; Vargas, P.R.; de Souza, C.F.; Netto, C.; Wajner, M.; Vargas, C.R. Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int. J. Dev. Neurosci. 2009, 27, 243-247.
33. Sanayama, Y.; Nagasaka, H.; Takayanagi, M.; Ohura, T.; Sakamato, O.; Ito, T.; Ishige-Wada, M.; Usui, H.; Yoshino, M.; Ohtake, A. et al. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol. Genet. Metab. 2011, 103, 220-225.
34. Schulpis, K.H.; Tsakiris, S.; Traeger-Synodinos, J.; Papassotiriou, I. Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria. Clin. Biochem. 2005, 38, 239-242.
35. Sitta, A.; Vanzin, C.S.; Biancini, G.B.; Manfredoni, V.; De Oliviera, A.B.; Wayhs, C.A.Y.; Ribas, G.O.S.; Giuliani, L.; Schwartz, I.V.D.; Bohrer, D. et al. Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients. Cell Mol. Neurobiol. 2011, 31, 429-436.
36. Hatanaka, N.; Nakaden, H.; Yamamoto, Y.; Matsuo, S.; Fujikawa, T.; Matsusue, S. Selenium Kinetics and Changes in Glutathione Peroxidase Activities in Patients Receiving Long-Term Parenteral Nutrition and Effects of Supplementation With Selenite. Nutrition 2000, 16, 22-26.
37. Kienzle-Hagen, M.E.; Pederzolli, C.D.; Sgaravatti, A.M.; Bridi, R.; Wajner, R.; Wannmacher, C.M.; Wyse, A.T.; Dutra-Filho, C.S. Experimental hyperphenylalaninemia provokes oxidative stress in rat brain. Biochim. Biophys. Acta 2000, 1586, 344-352.
38. Sitta, A.; Barschak, A.G.; Deon, M.; de Mari, J.F.; Barden, A.T.; Vanzin, C.S.; Biancini, G.B.; Schwartz, I.V.; Wajner, M.; Vargas, C.R. L-Carnitine blood levels and oxidative stress in treated phenylketonuria patients. Cell Mol. Neurobiol. 2009, 29, 211-218.
39. Preissler, T.; Bristot, I.J.; Costa, B.M.L.; Fernandes, E.K.; Rieger, E.; Bortoluzzi, V.T.; de Franceschi, I.D.; Dudra-Filho, C.S.; Moreira, J.C.F.; Wannmacher, C.M.D. Phenylalanine induces oxidative stress and decreases the viability of rat astrocytes: Possible relevance for the pathophysiology of neurodegeneration in phenylketonuria Metab. Brain Dis. 2016, 31, 529-537.
40. Schuck, P.F.; Malgarin, F.; Cararo, J.H.; Cardoso, F.; Streck, E.L.; Ferreira, G.C. Phenylketonuria pathophysiology: On the role of the metabolic alterations. Aging Dis. 2015, 6, 390-399.
41. Castillo, M.; Martinez-Cayuela, M.; Zafra, M.F.; Garcia-Peregrin, E. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis. Mol. Cell Biochem. 1991, 105, 21-25.
42. Shefer, S.; Tint, G.S.; Jean-Guillaume, D.; Daikhin, E.; Kendler, A.; Nguyen, L.B.; Yudkoff, M.; Dyer, C.A. Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and forebrain pathology in the PKU mouse? J. Neurosci. Res. 2000, 61, 549-563.
43. Colome, C.; Artuch, R.; Vilaseca, M.A.; Sierra, C.; Brandi, N.; Cambra, F.J.; Lambruschini, N.; Campistol, J. Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin. Biochem. 2002, 35, 81-84.
44. Hargreaves, I.P.; Heales, S.J.; Briddon, A.; Land, J.M.; Lee, P.J. Mononuclear cell coenzyme Q (coq) Concentration and mitochondrial respiratory chain succinate cytochrome C reductase (complex li-iii) activity in phenyloketonuric patiens. J. Inher. Metab. Dis. 2002, 25, 18.
45. Rech, V.C.; Feksa, L.R.; Dudra-Filho, C.S.; Wyse, A.T.D.S.; Wajner, M.; Wannmacher, C.M.D. Inhibition of the mitochondrial respiratory chain by phenylalanine in rat cerebral; cortex. Neurochem. Res. 2002, 27, 353-357.
46. Kyprianou, N.; Murphy, E.; Lee, P.; Hargreaves, I. Assessment of mitochondrial respiratory chain function in hyperphenylalaninemia. J. Inherit. Metab. 2009, 32, 289-296.
47. Przyrembel, H.; Bremer, H.J. Nutrition, physical growth, and bone density in treated phenylketonuria. Eur. J. Pediatr. 2000, 159, S129-S135.
48. Giovannini, M.; Verduci, E.; Salvatici, E.; Fiori, L.; Riva, E. Phenylketonuria: Dietary and therapeutic challenges. J. Inherit. Metab. Dis. 2007, 30, 145-152.
49. Poustie, V.J.; Wildgoose, J. Dietary interventions for phenylketonuria. Cochrane Libr. 2010, doi:10.1002/14651858.CD001304.pub2.
50. McMurry, M.P.; Chan, G.M.; Leonard, C.O.; Ernst, S.L. Bone mineral status in children with phenylketonuria—Relationship to nutritional intake and phenylalanine control. Am. J. Clin. Nutr. 1992, 55, 997-1004.
51. Wilke, B.C.; Vidailhet, M.; Richard, M.J.; Ducros, V.; Arnaud, J.; Favier, A. Trace elements balance in treated phenylketonuria children. Consequences of selenium deficiency on lipid peroxidation. Arch. Latinoam. Nutr. 1993, 43,119-122.
52. Ragsdale, S. Metal-carbon bonds in enzymes and cofactors. Coord. Chem. Rev. 2010, 254, 1948-1949.
53. Robert, M.; Rocha, J.C.; van Rijn, M.; Ahring, K.; Bélanger-Quintana, A.; MacDonald, A.; Dokoupil, K.; Ozel, H.G.; Lammardo, A.M.; Goyens, P. et al. Micronutrient status in phenylketonuria. Mol. Genet. Metab. 2013, 110, S6-S17.
54. Bohler, H.; Ulrich, K.; Endres, W.; Behbehani, A.W.; Wendel, U. Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria. Eur. J. Pediatr. 1991, 15, 425-428.
55. Gullcin, I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006, 78, 803-811.
56. Ribas, G.S.; Sitta, A.; Wajner, M.; Vargas, C.R. Oxidative stress in phenylketonuria: What is the evidence? Cell Mol. Neurobiol. 2011, 31, 653-662.
57. Dobson, C.M.; Wai, T.; Leclerc, D.; Wilson, A.; Wu, X.; Dore, C.; Hudson, T.; Rosenblatt, D.S.; Gravel, R.A. Identification of the gene responsible for the cblA complementation group of vitamin B12responsive methylmalonic acidemia based on analysis of prokaryotic gene arrangements. Proc. Natl. Acad. Sci. USA 2002, 99, 15554-15559.
58. Fenton, W.A.; Gravel, R.A.A.; Rosenblatt, D.S. Disorders of propionate and methylmalonate metabolism. In The Metabolic and Molecular Bases of Inherited Disease; Scriver, C.R., Beaudet, A.L., Sky, W.S., Valle, D., Eds.; McGraw-Hill: New York, NY, USA, 2011; pp. 2165-2193.
59. Treacy, E.; Arbour, L.; Chessex, P.; Graham, G.; Kasprzak, L.; Casey, K.; Bell, L.; Mamer, O.; Scriver, C.R. Glutathione deficiency as a complication of methylmalonic acidemia: Response to high doses of ascorbate. J. Pediatr. 1996, 129, 445-448.
60. Hoffmann, G.F.; Meier-Augenstein, W.; Stocker, S.; Surtees, R.; Rating, D.; Nyhan, W. Physiology and pathophysiology of organic acids in cerebrospinal fluid. J. Inherit. Metab. Dis. 1993, 16, 648-669.
61. Manoli, I.; Sloan, J.L.; Venditti, C.P. Isolated methylmalonic acidemia. In Genereviews [Internet]; Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Ledbetter, N., Mefford, H.C., Smith, R.J.H., et al., Eds.; University of Washington: Seattle, WA, USA; pp. 1993-2017.
62. Hayasaka, K.; Metoki, K.; Satoh, T.; Narisawa, K.; Tada, K.; Kawakami, T.; Matsuo, N.; Aoki, T. Comparison of cytosolic and mitochondrial enzyme alterations in the livers of propionic or methylmalonic acidemia: A reduction of cytochrome oxidase activity. Tohoku J. Exp. Med. 1982, 137, 329-333.
63. Richard, E.; Alvarez-Barrientos, A.; Perez, B.; Desviat, L.R.; Ugarte, M. Methylmalonic acidaemia leads to increased production reactive oxygen species and induction of apoptosis through the mitocondrial/caspase pathway. J. Pathol. 2007, 213, 453-461.
64. Lindblad, B.; Lindblad, B.S.; Olin, P.; Svanberg, B.; Zetterstrom, R. Methylmalonic academia. A disorder associated with acidosis, hyperlycaemia, and hyperlactatemia. Acta Paediatr. Scand. 1968, 57, 417-424.
65. Okun, J.C.; Horster, F.; Farkas, L.; Feyh, P.; Hinz, A.; Sauer, S.; Hoffman, G.F.; Unisicker, K.; Mayatepek, E.; Kolker, S. Neurodegeneration in Methylmalonic Aciduria Involves Inhibition of Complex II and the Tricarboxylic Acid Cycle, and Synergistically Acting Excitotoxicity. J. Biol. Chem. 2002, 277, 14674-14680.
66. Marisco, P.C.; Ribeiro, M.C.; Bonini, J.S.; Lima, T.T.; Mann, K.C.; Brenner, G.M.; Dutra-Filho, C.S.; Mello, C.F. Ammonia potentiates methylmalonic acid-induced convulsions and TBARS production. Exp. Neurol. 2003, 182, 455-460.
67. Krahenbuhl, S.; Chang, M.; Brass, E.P.; Hoppel, C.L. Decreased activities of ubiqunol; ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c: Oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin [C-lactam]-induced methylmalonic aciduria. J. Biol. Chem. 1991, 266, 20998-21003.
68. Pettenuzzo, L.F.; Ferreira, G.D.C.; Schmidt, A.L.; Dutra-Filho, C.S.; Wyse, A.T.S.; Wajner, M. Differential inhibitory effects of methylmalonic acid on respitratory chain complex activities in rat tissues. Int. J. Dev. Neurosci. 2006, 24, 45-52.
69. Chandler, R.J.; Zerfas, P.M.; Shanske, S.; Sloan, J.; Hoffman, V.; DiMauro, S.; Venditti, C.P. Mitochondrial dysfunction in mut methylmalonic academia. FASEB J. 2009, 23, 1252-1261.
70. De Keyzer, Y.; Valayannopoulos, V.; Benoist, J.F.; Batteux, F.; Lacaille, F.; Hubert, L.; Chretien, D.; Chadefeaux-Vekemans, B.; Niaudet, P.; Touati, G. et al. Multiple OXPHOS deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr. Res. 2009, 66, 91-95.
71. Kashtan, C.E.; Abousedira, M.; Rozen, S.; Manivel, J.C.; McCann, M.; Tuchman, M. Chronic administration of methylmaloic acid (MMA) to rats causes proteinuria and renal tubular injury (abstract). Pediatr. Res. 1998, 43, 309.
72. Zsengeller, Z.K.; Alkinovic, N.; Teot, L.A.; Korson, M.; Rodig, N.; Sloan, J.L.; Venditti, C.P.; Berry, G.T.; Rosen, S. Methylmalonic academia: A megamitochondrial disorder affecting the kidney. Pediatr. Nephrol. 2014, 29, 2139-2146.
73. De Souza, C.; Piesowicz, A.T.; Brett, E.M.; Leonard, J.V. Focal changes in the globi pallidi associated with neurological dysfunction in methylmalonic academia. Neuropediatrics 1989, 20, 199-201.
74. Brismar, J.; Ozand, P.T. CT and MR of the brain in disorders of propionate and methylmalonate metabolism. Am. J. Neuroradiol. 1994, 15, 1459-1473.
75. Larnaout, A.; Mongalgi, M.A.; Kaabachi, N.; Khiari, D.; Debbabi, A.; Mebazza, A.; Ben Hamida, M.; Hentati, F. Methylmalonic acidaemia with bilateral globus pallidus involvement: A neuropathological study. J. Inherit. Metab. Dis. 1998, 21, 639-644.
76. Martin, J.J.; van de Vyver, F.L.; Scholte, H.R.; Roodhooft, A.M.; Martin, C.C.; Luyt-Houwen, I.E. J. Neurol. Sci. 1988, 84, 189-200.
77. Trinh, B.C.; Melhem, E.R.; Barker, P.B. Multi-slice proton MR spectroscopy and diffusion-weighted imaging in methylmalonic acidemia: Report of two cases and review of the literature. Am. J. Neuroradiol. 2001, 22, 831-833.
78. Heidenreich, R.; Natowicz, M.; Hainline, B.E.; Berman, P.; Kelley, R.I.; Hillman, R.E.; Berry, G.T. Acute extrapyramidal syndrome in methylmalonic acidemia: “Metabolic stroke” involving the globus pallidus. J. Pediatr. 1988, 113, 1022-1027.
79. Brusque, A.M.; Borba Rosa, R.; Schuck, P.F.; Dalcin, K.B.; Ribeiro, C.A.J.; Silva, C.G.; Wannmacher, C.M.D.; Dutra-Filho, C.S.; Wyse, A.T.S.; Briones, P. et al. Inhibition of the mitochondrial respiratory chain complex activities in rat cerebral cortex by methylmalonic acid. Neurochem. Int. 2002, 40, 593-601.
80. Kolker, S.; Okun, J.G. Methylmalonic acid—An endogenous toxin? Cell Mol. Life Sci. 2005, 62, 621-624.
81. McLaughlin, B.A.; Nelson, D.; Silver, I.A.; Erecinska, M.; Chesselet, M.F. Methylmalonate toxicity in primary neuronal cultures. Neuroscience 1998, 86, 279-290.
82. Calabresi, P.; Gubellini, P.; Picconi, B.; Centonze, D.; Pisani, A.; Bonsi, P.; Greengard, P.; Hipskind, R.A.; Borrelli, E.; Bernardi, G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 2001, 21, 5110-5120.
83. Royes, L.F.; Fighera, M.R.; Furian, A.F.; Oliveira, M.S.; da Silva, L.G.; Malfatti, C.R.; Schneider, P.H.; Braga, A.L.; Wajner, M.; Mello, C.F. Creatine protects against the convulsive behaviour and lactate production elicited by the intrastriatal injection of methylmalonate. Neuroscience 2003, 118, 1079-1090. Erratum in: Neuroscience. 2004, 125, 533.
84. Fleck, J.; Ribeiro, M.C.; Schneider, C.M.; Sinhorin, V.D.; Rubin, M.A.; Mello, C.F. Intrastriatal malonate administration induces convulsive behaviour in rats. J. Inherit. Metab. Dis. 2004, 27, 211-219.
85. Atkuri, K.R.; Cowan, T.M.; Kwan, T.; Ng, A.; Herzenberg, L.A.; Herzenberg, LA.; Enns, G.M. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc. Natl. Acad. Sci. USA 2009, 106, 3941-3944.
86. Fontella, F.; Pulronick, V.; Gassen, E.; Wannmacher, C.M.D.; Klein, A.B.; Wajner, M.; Dutra-Filho, C.S. Propionic and L-methylmalonic acids induce oxidative stress in brain of young rats. Neuroreport 2000, 28, 541-544.
87. Manoli, I.; Myles, J.G.; Sloan, J.L.; Carrillo-Carrasco, N.; Morava, E.; Strauss, K.A.; Morton, H.; Venditti, C.P. A critical reappraisal of dietary practices in methylmalonic academia raises concerns about the safety of medical foods. Part 2: Cobalamin C deficiency. Genet. Med. 2016, 18, 396-404.
88. Manoli, I.; Sysol, J.R.; Li, L.; Houillier, P.; Garone, C.; Wang, C.; Zerfas, P.M.; Cusmano-Ozog, K.; Young, S.; Trivedi, N.S. et al. Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic academia. Proc. Natl. Acad. Sci. USA 2013, 110, 13552-13557.
89. Hargreaves, I.P.; Sheena, Y.; Land, J.M.; Heales, S.J. Glutathione deficiency in patients with mitochondrial disease: Implications for pathogenesis and treatment. J. Inherit. Metab. Dis. 2005, 28, 1-88.
90. Salmi, H.; Leonard, J.; Lapatto, R. Patients with organic acidaemias have an alteredthiol status. Acta Paediatr. 2012, 101, e505-e508.
91. Haas, D.; Niklowitz, P.; Horster, F.; Baumgartner, E.R.; Prasad, C.; Rodenburg, R.J.; Hoffmann, T.; Menke, T.; Okun, J.G. Coenzyme Q10 is decreased in fibroblasts of patients with methylmalonic aciduria but not in mevalonic aciduria. J. Inherit. Metab. Dis. 2009, 4, 570-575.
92. Hargreaves, I.P. Ubiquinone: Cholesterol’s reclusive cousin. Ann. Clin. Biochem. 2003, 40, 207-218.
93. Baumgarther, M.R.; Horster, F.; Dionisi-Vici, C.; Haliloglu, G.; Karall, D.; Chapman, K.A.; Huemer, M.; Hochuli, M.; Assoun, M.; Ballhausen, D. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J. Rare Dis. 2014, 9, 130.
94. Pinar-Sueiro, S.; Martinez-Fernondez, R.; Lage-Medines, S.; Aldamiz-Echevarria, L.; Vecino, E. Optic neuropathy in methylmalonic acidemia: The role of neuroprotection. J. Inherit. Metab. Dis. 2010, 3, S199-S203.
95. Williams, Z.R.; Hurley, P.E.; Altipamak, V.E.; Feldon, S.E.; Arnold, G.L.; Eggenberger, E.; Mejico, L.J. Late onset optic neuropathy in methylmalonic and propionic academia. Am. J. Ophthalmol. 2009, 147, 929-933.
96. Leipnitz, G.; Amaral, A.U.; Fernandes, C.G.; Seminotti, B.; Zanatta, A.; Knebel, L.A.; Vargas, C.R.; Wajner, M. Pristanic acid promotes oxidative stress in brain damage in peroxisomal disorders. Brain Res. 2011, 1382, 259-265.
97. Weller, S.; Gould, S.J.; Valle, D. Peroxisomes biogenesis disorders. Ann. Rev. Genom. Hum. Genet. 2003, 4, 165-211.
98. Lee, Y.M.; Sumpter, R.; Zou, Z.; Sirasanagandia, S.; Wei, Y.; Mishra, P.; Rosewich, H.; Crane, D.I.; Levine, B. Peroxisomal protein PEX13 functions in selective autophagy. EMBO Rep. 2017, 18, 48-60.
99. White, A.L.; Modaff, P.; Holland-Morris, P.; Pauli, P.M. Natural history of rhizomelic chondrodysplasia punctate. Am. J. Med. Genet. 2003, 118, 332-342.
100. Ferrer, I.; Aubourg, P.; Pujol, A. General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol. 2010, 20, 817-830.
101. Moser, H.; Smith, K.D.; Watkins, P.A.; Powers, J.; Moser, A.B. X-linked adrenoleukodystrophy. In The Metabolic and Molecular Bases of Inherited Disease, 8th ed.; Scriver, C., Ed.; McGraw-Hill: New-York, NY, USA, 2001; Volume 2, pp. 3257-3301.
102. Powers, J.M.; DeCiero, D.P.; Ito, M.; Moser, A.B.; Moser, H.W. Adrenomyeloneuropathy: A neuropathologic review featuring its noninflammatory myelopathy. J. Neuropathol. Exp. Neurol. 2000, 59, 89-102.
103. Wanders, R.J.A.; van Roermund, W.T.; Shutgens, R.B.H.; Barth, P.G.; Heymans, H.S.A.; van den Bosch, H.; Tager, J.M. The inborn errors of peroxisomal beta-oxidation. A review. J. Inher. Metab. Dis. 1990, 13, 4-36.
104. Schulz, H. Beta oxidation of fatty acids. Biochim. Biophys. Acta 1991, 1081, 109-120.
105. Poirier, Y.; Antonenkov, V.D.; Glumoff, T.; Hiltunen, J.K. Peroxisomal beta-oxidation- a metabolic pathway with multiple functions. Biochim. Biophys. Acta 2006, 1763, 1413-1426.
106. Angermuller, S.; Bruder, G.; Volkl, A.; Wesch, H.; Fahimi, H.D. Localization of xanthine oxidase in crystalline cores of peroxisomes. A cytochemical and biochemical study. Eur. J. Cell Biol. 1987, 45, 137-144.
107. Lismont, C.; Nordgen, M.; van Veldhoven, P.P.; Fransen, M. Redox interplay between mitochondria and peroxisomes. Front. Cell Dev. Biol. 2015, 3, 1-19.
108. Vargas, C.R.; Wajner, M.; Sirtori, L.R.; Goulart, L.; Chiochetta, M.; Coelho, D.; Latini, A.; Llesuy, S.; Bello-Klein, A.; Giugliani, R. et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta 2004, 1688, 26-32.
109. El-Bassyouni, H.T.; Abel Maksoud, S.A.; Salem, F.A.; Badr El-Deen, R.; Abdel Aziz, H.; Thomas, M.M. Evidence of oxidative stress in peroxisomal disorders. Singap. Med. J. 2012, 53, 608.
110. Schrader, M.; Fahimi, H.D. Mammalian peroxisomes and reactive oxygen species. Histochem. Cell Biol. 2004, 122, 383-393.
111. Fransen, M.; Nordgren, M.; Wang, B.; Apanasets, O. Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochim. Biophys. Acta 2012, 1822, 1363-1373.
112. Fujiwara, C.; Imamure, A.; Hashiguchi, V.; Shimozawa, N.; Suzuki, Y.; Kondo, N.; Imanaka, T.; Tsukamoto, T.; Osumi, T. Catalase-less Peroxisomes: Implication in the milder forms of peroxisome biogenesis disorder. J. Biol. Chem. 2000, 275, 37271-37277.
113. Baumgart, E.; Vanhorebeek, I.; Grabenbauer, M.; Borgers, M.; Declercq, P.E.; Fahimi, H.D.; Baes, M. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model of Zellweger syndrome (PEX5 knock out mouse). Am. J. Pathol. 2001, 159, 1477-1494.
114. Schrakamp, G.; Schalkwijk, C.G.; Schutgens, R.B.; Wanders, R.J.; Tager, J.M.; van den Bosch, H. Plasmalogen biosynthesis in peroxisomal disorders: Fatty alcohol versus alkylglycerol precursors. J. Lipid Res. 1988, 29, 325-334.
115. Wood, C.S.; Koepke, J.I.; Teng, H.; Boucher, K.K.; Katz, S.; Chang, P.; Terlecky, L.J.; Papanayotou, I.; Walton, P.A.; Terlecky, S.R. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic 2006, 7, 97-107.
116. Wanders, R.J.; Schutgens, R.B.; Barth, P.G. Peroxisomal disorders: A review. J. Neuropathol. Exp. Neurol. 1995, 54, 726-739.
117. Lopez-Erauskin, J.; Galino, J.; Ruiz, M.; Cuezva, J.M.; Fabregat, I.; Cacabelos, D.; Boada, J.; Martinez, J.; Ferrer, I.; Pamplona, R. et al. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum. Mol. Genet. 2013, 22, 3296-3305.
118. Ho, J.K.; Moser, H.; Kishimoto, Y.; Hamilton, J.A. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Investig. 1995, 96, 1455-1463.
119. Sarnat, H.B.; Machin, G.; Darwish, H.Z.; Rubin, S.Z. Mitochondrial myopathy of cerebrohepato-renal (Zellweger) syndrome. Can. J. Neurol. Sci. 1983, 10, 170-177.
120. Muller-Hocker, J.; Walther, J.R.; Bise, K.; Pongratz, D.; Hubner, G. Mitochondrial myopathy with loosely coupled oxidative phosphorylation in a case of Zellweger syndrome. Virchows Arch. B Cell Pathol. Zell-Pathol. 1984, 45, 125-138.
121. Wolff, J.; Nyhanf, W.L.; Powell, H.; Takahashi, D.; Hutzler, J.; Hajra, A.K.; Datta, N.S.; Singh, I.; Moser, H.W. Myopathy in an infant with a fatal peroxisomal disorder. Pediatr. Neurol. 1986, 2, 141.
122. Powers, J.M.; Pei, Z.; Heinzer, A.K.; Deering, R.; Moser, A.B.; Moser, H.W.; Watkins, P.A.; Smith, K.D. Adreno-leukodystrophy: Oxidative stress of mice and men. J. Neuropathol. Exp. Neurol. 2005, 64, 1067-1079.
123. Fourcade, S.; Ruiz, M.; Guilera, C.; Hahnen, E.; Brichta, L.; Naudi, A.; Portero-Otin, M.; Dacremont, G.; Cartier, N.; Wanders, R. et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum. Mol. Genet. 2010, 19, 2005-2014.
124. Salpietro, V.; Phadke, R.; Saggar, A.; Hargreaves, I.P.; Yates, R.; Fokoloros, C.; Mankad, K.; Hertecant, J.; Ruggieri, M.; McCormick, D. et al. Zellweger syndrome and secondary mitochondrial myopathy. Eur. J. Pediatr. 2015, 174, 557-563.
125. Fourcade, S.; Lopez-Erauskin, J.; Galino, J.; Duval, C.; Naudi, A.; Jove, M.; Kemp, S.; Villarroya, F.; Ferrer, I.; Pamplona, R. et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet. 2008, 17, 1762-1773.
126. Lopez-Erauskin, J.; Galino, J.; Bianchi, P.; Fourcade, S.; Andreu, A.L.; Ferrer, I.; Munoz-Pinedo, C.; Pujol, A. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain 2012, 135, 3584-3598.
127. Singh, I.; Pujol, A. Pathomechanisms underlying X-adrenoleukodystrophy: A three-hit hypothesis. Brain Pathol. 2010, 20, 838-844.
128. Galea, E.; Launay, N.; Portero-Otin, M.; Ruiz, M.; Pamplona, R.; Aubourg, P.; Ferrer, I.; Pujol, A. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases? Biochim. Biophys. Acta 2012, 9, 1475-1488.
129. Galino, J.; Ruiz, M.; Fourcade, S.; Schluter, A.; Lopez-Erauskin, J.; Guilera, C.; Jove, M.; Naudi, A.; Garcia-Arumi, E.; Andreu, A.L. et al. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid. Redox Signal. 2011, 15, 2095-2107.
130. Lopez-Erauskin, J.; Fourcade, S.; Galino, J.; Ruiz, M.; Schluter, A.; Naudi, A.; Jove, M.; Portero-Otin, M.; Pamplona, R.; Ferrer, I. et al. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann. Neurol. 2011, 70, 84-92.
131. Marchetti, D.P.; Donida, B.; Deon, M.; Jacques, C.E.; Jardim, L.B.; Vargas, C.R. In vitro effects of N-acetyl-L-cysteine on glutathione and sulfhryl levels in X-linked adrenoleukodystrophy patients. Clin. Biomed. Res. 2017, 37, 33-37.
132. Ferdinandusse, S.; Finckh, B.; de Hingh, Y.C.; Stroomer, L.E.; Denis, S.; Kohlschutter, A.; Wanders, R.J. Evidence for increased oxidative stress in peroxisomal D-bifunctional protein deficiency. Mol. Genet. Metab. 2003, 79, 281-287.
133. Huang, J.; Liu, X.; Tang, L.L.; Long, J.T.; Zhu, J.; Hua, R.X.; Li, J. XPG gene polymorphisms and cancer susceptibility: Evidence from 47 studies. Oncotarget 2017, doi:10.18632/oncotarget.16146.
134. Carre, G.; Marelli, C.; Anheim, M.; Geny, C.; Renaud, M.; Rezvani, H.R.; Koenig, M.; Guissart, C; Tranchant, C. Xeroderma pigmentosum complementation group F: A rare cause of cerebellar ataxia with chorea. J. Neurol. Sci. 2017, 376, 198-201.
135. Niedernhofer, L.J.; Bohr, V.A.; Sander, M.; Kraemer, K.H. Xeroderma pigmentosum and other diseases of human premature aging and DNA repair: Molecules to patients. Mech. Ageing Dev. 2011, 132, 340-347.
136. DiGiovanna, J.J.; Kraemer, K.H. Shining a light on xeroderma pigmentosum. J. Investig. Dermatol. 2012, 132, 785-796.
137. Copeland, N.E.; Hanke, C.W.; Michalak, J.A. The molecular basis of xeroderma pigmentosum. Dermatol. Surg. 1997, 23, 447-455.
138. Wang, H.T.; Choi, B.; Tang, M.S. Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts. Proc. Natl. Acad. Sci. USA 2010, 107, 12180-12185.
139. Pascucci, B.; D’errico, M.; Parlanti, E.; Giovannini, S.; Dogliotti, E. Role of nucleotide excision repair proteins in oxidative DNA damage repair: An updating. Biochemistry 2011, 76, 4-15.
140. Hayashi, M.; Itoh, M.; Araki, S.; Kumada, S.; Shioda, K.; Tamagawa, K.; Mizutani, T.; Morimatsu, Y.; Minagawa, M.; Oda, M. Oxidative stress and disturbed glutamate transport in hereditary nucleotide repair disorders. J. Neuropathol. Exp. Neurol. 2001, 60, 350-356.
141. Murai, M.; Enokido, Y.; Inamura, N.; Yoshino, M.; Nakatsu, Y.; van der Horst, G.T.; Hoeijmakers, J.H.; Tanaka, K.; Hatanaka, H. Early postnatal ataxia and abnormal cerebellar development in mice lacking Xeroderma pigmentosum Group A and Cockayne syndrome Group B DNA repair genes. Proc. Natl. Acad. Sci. USA 2001, 98, 13379-13384.
142. Brooks, P.J. The 8,5′-cyclopurine-2′-deoxynucleosides: Candidate neurodegenerative DNA lesions in xeroderma pigmentosum, and unique probes of transcription and nucleotide excision repair. DNA Repair 2008, 7, 1168-1179.
143. Hayashi, M.; Ahmad, S.I.; Hanaoka, F. Roles of oxidative stress in xeroderma pigmentosum. Adv. Exp. Med. Biol. 2008, 637, 120-127.
144. Melis, J.P.; van Steeg, H.; Luijten, M. Oxidative DNA damage and nucleotide excision repair. Antioxid. Redox Signal. 2013, 18, 2409-2419.
145. Li, L.; Bales, E.S.; Peterson, C.A.; Legerski, R.J. Characterization of molecular defects in xeroderma pigmentosum group C. Nat. Genet. 1993, 5, 413-417.
146. Rezvani, H.R.; Rossignol, R.; Ali, N.; Bernard, G.; Tang, X.; Yang, H.S.; Jouary, T.; de Verneuil, H.; Taieb, A.; Kim, A.L. et al. XPC silencing in normal human keratinocytes triggers metabolic alterations through NOX-1 activation-mediated reactive oxygen species. Biochim. Biophys. Acta Bioenerg. 2011, 1807, 609-619.
147. Hosseini, M.; Mahfouf, W.; Serrano-Sanchez, M.; Raad, H.; Harfouche, G.; Bonneu, M.; Claverol, S.; Mazurier, F.; Rossignol, R.; Taieb, A. et al. Premature Skin Aging Features Rescued by Inhibition of NADPH Oxidase Activity in XPC-Deficient Mice. J. Investig. Dermatol. 2015, 135, 1108-1118.
148. Fang, E.F.; Scheibye-Knudsen, M.; Brace, L.E.; Kassahun, H.; Sengupta, T.; Nilsen, H.; Mitchell, J.R.; Croteau, D.L.; Bohr, V.A. Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD(+)/SIRT1 Reduction. Cell 2014, 157, 882-896.
149. Osellame, L.D.; Rahim, A.A.; Hargreaves, I.P.; Gegg, M.E.; Richard-Londt, A.; Brandner, S.; Waddington, S.N.; Schapira, A.H.; Duchen, M.R. Mitochondria and quality control defects in a mouse model of Gaucher disease- links to Parkinson’s disease. Cell Metab. 2013, 17, 941-953.
150. Reza Rezvani, H.; Taieb, A. Le xeroderma pigmentosum. M/S Med. Sci. 2011, 27, 467.
151. Liu, J.; Fang, H.; Chi, Z.; Wu, Z.; Wei, D.; Mo, D.; Niu, K.; Balajee, A.S.; Hei, T.K.; Nie, L. et al. XPD localizes in mitochondria and protects the mitochondrial genome from oxidative DNA damage. Nucl. Acids Res. 2015, doi:10.1093/nar/gkv472.
152. Mori, M.P.; Costa, R.P.; Soltys, D.T.; Freire, T.D.S.; Rossato, F.A.; Amigo, I.; Kowaltowski, A.J.; Vercesi, A.E.; de Souza-Pinto, N.C. Lack of XPC leads to a a shift between respiratory complexes I and II but sensitizes cells to mitochondrial stress. Sci. Rep. 2017, 7, 155.
153. Rothe, M.; Werner, D.; Thielmann, H.W. Enhanced expression of mitochondrial genes in xeroderma pigmentosum fibroblast strains from various complementation groups. J. Cancer Res. Clin. Oncol. 1993, 119, 675-684.
154. Berg, D.; Otley, C.C. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis and management. J. Am. Acad. Dermatol. 2002, 47, 1-17.
155. Boesch, P.; Weber-Lotfi, F.; Ibrahim, N.; Tarasenko, V.; Cosset, A.; Paulus, F.; Lightowlers, R.N.; Dietrich, A. DNA repair in organelles: Pathways, organisation, regulation, relevance in disease and aging. Biochim. Biophys. Acta 2011, 1813, 186-200.
156. Quillet, X.; Chevallier-Lagente, O.; Zeng, L.; Calvayrac, R.; Mezzina, M.; Sarasin, A.; Vuillaume, M. Retroviral-mediated correction of DNA repair defect in xeroderma pigmentosa cells is associated with recovery of catalase activity. Mutat. Res. DNA Repair 1997, 385, 235-242.
157. Taneka, J.; Nagai, T.; Okada, S. Serum concentration of coenzyme Q in xeroderma pigmentosum. Rinsho Shinkeigaku Clin. Neurol. 1998, 38, 57-59.
158. Goncalves-Maia, M.; Magnaldo, T. Genetic therapy of xeroderma pigmentosa, analysis of strategies and translation. Exp. Opin. Orphan Drugs 2017, 5, 5-17.
159. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.; Sibbald, W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101, 1644-1655.
160. Chertow, G.M.; Burdick, E.; Honour, M.; Bonventre, J.V.; Bates, D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephr. 2005, 16, 3365-3370.
161. Uchino, S.; Kellum, J.A.; Bellomo, R.; Doig, G.S.; Morimatsu, H.; Morgera, S.; Achetz, M.; Tan, I.; Bouman, C.; Macedo, E. et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005, 294, 813-818.
162. Bagshaw, S.M.; Uchino, S.; Bellomo, R.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; Gibney, N. et al. Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin. J. Am. Soc. Nephrol. 2007, 2, 431-439.
163. Keir, I.; Kellum, J.A. Acute kidney injury in severe sepsis: Pathophysiology, diagnosis, and treatment recommendations. J. Veter. Emerg. Crit. Care 2015, 25, 200-209.
164. Abraham, E.; Singer, M. Mechanisms of sepsis-induced organ dysfunction. Crit. Care Med. 2007, 35, 2408-2416.
165. Martin, G.S.; Mannino, D.M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2000, 348, 1546-1554.
166. Weycker, D.; Akhras, K.S.; Edelsberg, J.; Angus, D.C.; Oster, G. Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 2003, 31, 2316-2323.
167. Jackson, J.C.; Girard, T.D.; Gordon, S.M.; Thompson, J.L.; Shintani, A.K.; Thomason, J.W.W.; Pun, B.T.; Canonico, A.E.; Dunn, J.G.; Bernard, G.R. et al. Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial. Am. J. Respir. Crit. Care Med. 2010, 182, 183-191.
168. Iwashyna, T.J.; Ely, E.W.; Smith, D.M.; Langa, K.M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010, 304, 1787-1794.
169. Trumbeckaite, S.; Opalka, J.R.; Neuhof, C.; Zierz, S.; Gellerich, F.N. Different sensitivity of a rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. Eur. J. Biochem. 2001, 268, 1422-1429.
170. Belcher, E.; Mitchell, J.; Evans, T. Myocardial dysfunction in sepsis: No role for NO. Heart 2000, 87, 507-509.
171. Singer, M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Landes Biosci. 2014, 5, 66-72.
172. Quoilin, C.; Mouithys-Mickalad, A.; Lecart, S.; Fontaine-Aupart, M.P.; Hoebeke, M. Evidence of oxidative stress and mitochondrial respiratory chain dysfunction in an in vitro model of sepsis-induced kidney injury. Biochim. Biophys. Acta Bioenerg. 2014, 1837, 1790-1800.
173. Moncada, S.; Erusalimsky, J.D. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat. Rev. Mol. Cell Biol. 2002, 3, 214-220.
174. Adrie, C.; Bachelet, M.; Vayssier-Taussat, M.; Russo-Marie, F.; Bouchaert, I.; Adib-Conquy, M.; Cavaillon, J.M.; Pinski, M.R.; Dhainaut, J.F.; Polla, B.S. Mitochondrial membrane potential and apoptosis in peripheral blood monocytes in severe human sepsis. Am. J. Respir. Crit. Care Med. 2001, 164, 389-395.
175. Gellerich, F.N.; Trumbeckaite, S.; Opalka, J.R.; Gellerich, J.F.; Chen, Y.; Zierz, S.; Werdan, K.; Neuhof, C.; Redl, H. Mitochondrial dysfunction in sepsis: Evidence from bacteraemic baboons and endotoxaemic rabbits. Biosci. Rep. 2002, 22, 99-113.
176. Sener, G.; Toklu, H.; Ercan, F.; Erkanli, G. Protective effect of β-glucan against oxidative organ injury in a rat model of sepsis. Int. Immunopharmacol. 2005, 5, 1387-1396.
177. Kim, J-Y.; Lee, S-M. Vitamins C and E protect hepatic cytochrome P450 dysfunction induced by polymicrobial sepsis. Eur. J. Pharmacol. 2006, 534, 202-209.
178. Mishra, V.; Baines, M.; Perry, S.E.; McLaughlin, P.J.; Carson, J.; Wenstone, R.; Shenkin, A. Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. Clin. Nutr. 2007, 26, 41-50.
179. Angstwurm, M.W.; Engelman, L.; Zimmermann, T.; Lehmann, C.; Spes, C.H.; Abel, P.; Strau, R.; Meier-Hellmann, A.; Insel, R.; Radke, J. et al. Selenium in intensive care (SIC): Results of a prospective randomized, placebo-controlled, multiple-centre study in patients with severe systemic inflammatory response syndrome, sepsis and septic shock. Crit. Care Med. 2007, 35, 118-126.
180. Galley, H.F. Oxidative stress and mitochondrial dysfunction in sepsis. Brit. J. Anaesth. 2011, 107, 57-64.
181. Radi, R.; Cassina, A.; Hodara, R.; Quijano, C.; Castro, L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med. 2002, 33, 1451-1464.
182. Laganiere, S.; Yu, B.P. Modulation of membrane phospholipid fatty acid composition and food restriction. Gerontology 1993, 39, 7-18.
183. Kang, D.; Hamasaki, N. Mitochondrial oxidative stress and mitochondrial DNA. Clin. Chem. Lab. Med. 2003, 41, 1281-1288.
184. Hargreaves, I.P.; Duncan, A.J.; Wu, L.; Agrawal, A.; Land, J.M.; Heales, S.J. Inhibition of mitochondrial complex IV leads to secondary loss complex II-III activity: Implications for the pathogenesis and treatment of mitochondrial encephalomyopathies. Mitochondrion 2007, 7, 284-287.
185. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315-424.
186. Frijhoff, J.; Winyard, P.G.; Zarkovic, N.; Davies, S.S.; Stocker, R.; Cheng, D.; Gasparovic, A.C. Clinical Relevance of Biomarkers of Oxidative Stress. Antioxid. Redox Signal. 2015, 23, 1144-1170.
187. 10as an internal standard. Clin. Chem. 2005, 51, 2380-2382.
188. Enns, G.M.; Cowan, T.M. Glutathione as a Redox Biomarker in Mitochondrial Disease-Implications for Therapy. J. Clin. Med. 2017, doi:10.3390/jcm6050050.
189. Enns, G.M.; Kinsma, S.L.; Perlman, S.L.; Spicer, K.M.; Abdenur, J.E.; Cohen, B.H.; Thoolen, M. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol. Genet. Metab. 2012, 105, 91-102.
190. Homstrom, K.H.; Baird, L.; Zhang, Y.; Hargreaves, I.; Chalasani, A.; Land, J.M.; Abramov, A.Y. NrF2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open 2013, 2, 761-770.